Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes

Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes Clinical Trial

Official title: Prospective, Multicenter, Randomized, and Comparative Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes

Status Recruiting

Clinical Trial Summary

The clinical study determines the effect of Evogliptin in patients with type 2 diabetes mellitus and chronic hepatitis B to confirm the improvement of hepatic fibrosis.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Fibrosis
• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic
• Liver Cirrhosis

• NCT number: NCT04584242
• Study type: Interventional
• Source: Yonsei University
• Contact: Seung Up Kim
• Phone: +82-2228-1982
• Email: ksukorea@yuhs.ac
• Status: Recruiting
• Phase: Phase 4
• Start date: September 3, 2020
• Completion date: May 2022